Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized study of ublituximab and umbralisib with or without bendamustine in previously treated non-Hodgkin lymphoma
MOH_2018-04-30_002351Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more comparing Ublituximab + umbralisib, Umbralisib monotherapy and Ublituximab + umbralisib + bendamustine (3 arms). Started Mar 2018; status: completed.
02
Drugs
umbralisibublituximabbendamustine
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on MOH_2018-04-30_002351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-30_002351.